A stratified treatment model for “NET-high” RA could be guided by biomarkers such as elevated levels of serum CitH3, MPO-DNA complexes, anti-PAD4 antibodies, and/or impaired DNase I activity. The gene discussed is MPO; the disease is rheumatoid arthritis.